Literature DB >> 2157568

Induction of B cell responsiveness to growth factors by Epstein-Barr virus conversion: comparison of endogenous factors and interleukin-1.

B A Blazar1, A M Murphy.   

Abstract

Immortalized B lymphocytes produce a factor(s) that stimulates growth of B cell lines carrying Epstein-Barr virus (EBV). Stimulatory supernatants derived from B cells also exhibit interleukin-1 (IL-1) activity in costimulator assays with the D10.G4.1 helper T cell line. Experiments with purified macrophage-derived IL-1 and recombinant IL-1 beta demonstrate that IL-1 stimulates proliferation of the cell lines that respond to the factors from B lymphocyte lines. One B cell line, Ramos, an EBV-Burkitt's lymphoma, contrasts with other B cell lines in that it is refractory to the growth enhancing effects of B cell conditioned medium and macrophage-derived IL-1. When EBV was introduced into Ramos cells, growth was enhanced by the factor(s) in B cell conditioned medium (six out of seven lines); growth of EBV-converted Ramos lines (six out of seven lines) also was enhanced by IL-1. These findings demonstrate that infection of a non-responsive transformed B lymphocyte by EBV induces cellular responsiveness to factor-mediated growth stimulation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157568      PMCID: PMC1535234          DOI: 10.1111/j.1365-2249.1990.tb06442.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  43 in total

1.  An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection.

Authors:  G Klein; B Giovanella; A Westman; J S Stehlin; D Mumford
Journal:  Intervirology       Date:  1975       Impact factor: 1.763

2.  Further studies on the differences in serum dependence in EBV negative lymphoma lines and their in vitro EBV converted, virus-genome carrying sublines.

Authors:  M Steinitz; G Klein
Journal:  Eur J Cancer       Date:  1977-11       Impact factor: 9.162

3.  Purification to homogeneity and NH2-terminal amino acid sequence of a novel interleukin 1 species derived from a human B cell line.

Authors:  L Rimsky; H Wakasugi; P Ferrara; P Robin; J Capdevielle; T Tursz; D Fradelizi; J Bertoglio
Journal:  J Immunol       Date:  1986-05-01       Impact factor: 5.422

4.  Cell-surface immunoglobulin and insulin receptor expression in an EBV-negative lymphoma cell line and its EBV-converted sublines.

Authors:  G Spira; P Aman; N Koide; G Lundin; G Klein; K Hall
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

5.  Relationship between the amounts of EBV-DNA and EBNA per cell, clonability and tumorigenicity in two ebv-negative lymphoma lines and their EBV-converted sublines.

Authors:  I Ernberg; G Klein; B C Giovanella; J Stehlin; K J McCormick; M Andersson-Anvret; P Aman; D Killander
Journal:  Int J Cancer       Date:  1983-02-15       Impact factor: 7.396

Review 6.  Interleukin 1 and T cell activation.

Authors:  S B Mizel
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

7.  Antigen presentation by human B cells: T cell proliferation induced by Epstein Barr virus B lymphoblastoid cells.

Authors:  T Issekutz; E Chu; R S Geha
Journal:  J Immunol       Date:  1982-10       Impact factor: 5.422

8.  Identification of a macrophage antigen-processing event required for I-region-restricted antigen presentation to T lymphocytes.

Authors:  K Ziegler; E R Unanue
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

9.  In vitro production of interleukin 1 by normal and malignant human B lymphocytes.

Authors:  V Pistoia; F Cozzolino; A Rubartelli; M Torcia; S Roncella; M Ferrarini
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

10.  Purification to homogeneity of a high molecular weight human B cell growth factor; demonstration of specific binding to activated B cells; and development of a monoclonal antibody to the factor.

Authors:  J L Ambrus; C H Jurgensen; E J Brown; A S Fauci
Journal:  J Exp Med       Date:  1985-10-01       Impact factor: 14.307

View more
  4 in total

1.  Cytokine production in a whole-blood assay after Epstein-Barr virus infection in vivo.

Authors:  M W Hornef; H J Wagner; A Kruse; H Kirchner
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

2.  Morphologic and immunophenotypic characterization of a cell line derived from liver tissue with Epstein-Barr virus associated post-transplant lymphoproliferative disease.

Authors:  P S Randhawa; A Zeevi; C Alvares; S Gollin; R Agostini; E Yunis; S Saidman; L Contis; A J Demetris; M A Nalesnik
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-06       Impact factor: 2.416

Review 3.  Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD.

Authors:  G Tosato; J Teruya-Feldstein; J Setsuda; S E Pike; K D Jones; E S Jaffe
Journal:  Springer Semin Immunopathol       Date:  1998

4.  Widespread evidence of viral miRNAs targeting host pathways.

Authors:  Joseph W Carl; Joanne Trgovcich; Sridhar Hannenhalli
Journal:  BMC Bioinformatics       Date:  2013-01-21       Impact factor: 3.169

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.